Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

NCT06444087 · tracked via the Priya Life Science France tracker

Sponsor

Novartis Pharmaceuticals

Phase

Observational

Started

2024-06-17

Last updated

2026-01-29

Condition(s) studied

Hidradenitis Suppurativa

Investigational drug(s) / intervention(s)

secukinumab

secukinumab: This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Study summary

The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.

Eligibility

Sex

ALL

Min age

18 Years

Max age

99 Years

Healthy volunteers

Inclusion Criteria: 1. Male and female patients ≥ 18 years old, 2. Patients who do not object to participation in the study, 3. Diagnosis of HS clinically confirmed, 4. Initiation of secukinumab treatment for HS in compliance with the summary of product characteristics, 5. The physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation. Exclusion Criteria: 1. Patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study, 2. Patients participating in a clinical trial.

Primary outcome measure(s)

Proportion of patients achieving at least 30% reduction of the NRS score for at least one the assessed symptoms — Baseline, month 12
Patients will provide an assessment of pain, oozing and bad smell based on three numeric rating scales (NRS). The most common form of the scale is a horizontal line with a numeric scale ranging from 0 to 10, 0 corresponding to "no symptoms" and 10 being the worst possible symptom. At each visit, these three assessments will cover the last seven days.

Trial sites (22)

Facility	City	Region
Novartis Investigative Site	Nice	France
Novartis Investigative Site	Antony	France
Novartis Investigative Site	Bordeaux	France
Novartis Investigative Site	Brest	France
Novartis Investigative Site	Calais	France
Novartis Investigative Site	Dijon	France
Novartis Investigative Site	La Rochelle	France
Novartis Investigative Site	Le Mans	France
Novartis Investigative Site	Lille	France
Novartis Investigative Site	Lorient	France
Novartis Investigative Site	Lyon	France
Novartis Investigative Site	Marseille	France
Novartis Investigative Site	Martigues	France
Novartis Investigative Site	Montpellier	France
Novartis Investigative Site	Nantes	France
Novartis Investigative Site	Paris	France
Novartis Investigative Site	Rodez	France
Novartis Investigative Site	Rouen	France
Novartis Investigative Site	Saint-Mandé	France
Novartis Investigative Site	Saint-Pierre	France
Novartis Investigative Site	Toulouse	France
Novartis Investigative Site	Vannes	France

On this site

📄 Cosentyx (secukinumab) drug profile →

More Novartis Pharmaceuticals trials in France

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia Recruiting

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) Active, not recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). Recruiting

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia Active, not recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis Recruiting

Other trials for the same condition

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Active, not recruiting

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa Enrolling by invitation

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06444087 on ClinicalTrials.gov ↗ ← All trials in France